{"url":"https://newsforagent.com/news/2026-10-24/nanobiotix-melanoma-phase-1-response-rate","markdown_url":"https://newsforagent.com/news/2026-10-24/nanobiotix-melanoma-phase-1-response-rate.md","title":"Nanobiotix Melanoma Data Show 41.7% Response Rate","headline":"Nanobiotix Reports 41.7% Response Rate in Anti-PD-1-Resistant Melanoma Study","description":"Nanobiotix's JNJ-1900 with checkpoint inhibitors produced a 41.7% response rate and 17.8-month median survival in 24 anti-PD-1-resistant melanoma patients.","section":"Research & Clinical Trials","published_at":"2026-10-24T11:40:40+00:00","modified_at":"2026-10-24T11:40:40+00:00","author":"News Desk","key_takeaways":["Nanobiotix reported a 41.7% overall response rate, including 4 complete responses, among 24 patients with anti-PD-1-resistant primary cutaneous melanoma.","Median overall survival reached 17.8 months and median progression-free survival was 6.9 months in the single-arm Phase 1 Study 1100.","Investigators concluded the preliminary findings warrant further evaluation in randomized clinical trials for patients naive or refractory to anti-PD-1."],"companies":[{"name":"Nanobiotix","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00027pr/nanobiotix","website":"http://www.nanobiotix.com"}],"source":{"publisher":"TradingView","title":"NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma","url":"https://www.tradingview.com/news/globenewswire:71007384b094b:0-nanobiotix-announces-final-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-with-immune-checkpoint-inhibitors-as-a-2l-therapy-in-anti-pd-1-resistant-primary-cutaneous-melanoma/"},"other_sources":[],"tags":["Research & Clinical Trials","Nanobiotix"],"body_markdown":"[Nanobiotix](https://akta.pro/company-profiles/00027pr/nanobiotix) reported final data from a Phase 1 study of JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors in 24 patients with anti-PD-1-resistant primary cutaneous melanoma, showing a 41.7% overall response rate and a median overall survival of 17.8 months. The results were presented at the 2026 Congress of the European Society for Medical Oncology, [TradingView](https://www.tradingview.com/news/globenewswire:71007384b094b:0-nanobiotix-announces-final-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-with-immune-checkpoint-inhibitors-as-a-2l-therapy-in-anti-pd-1-resistant-primary-cutaneous-melanoma/) reported.\n\n## How the Phase 1 Study 1100 Data Read Out\n\nAll 24 heavily pre-treated patients had advanced primary cutaneous melanoma resistant to anti-PD-1, and 14 had stage IV disease. Half had received anti-CTLA-4 therapy, 33.3% anti-LAG-3 and 25% T-VEC, while 87.5% had immunotherapy as their most recent treatment. Patients received a one-time intratumoral injection of JNJ-1900 (NBTXR3) at the recommended Phase 2 dose, followed by stereotactic body radiotherapy to the injected lesion and then nivolumab or pembrolizumab.\n\nThe overall response rate was 41.7% (10/24) per RECIST 1.1, including 4 complete responses, and the disease control rate was 75% (18/24). Responses appeared in injected lesions at 45.8% (11/24 evaluable patients) and in non-injected lesions at 30.0% (3/10 evaluable patients). Median progression-free survival was 6.9 months.\n\n\"In this study, a single injection followed by a short course of stereotactic radiotherapy was feasible across a wide range of tumor sizes and locations, and we saw responses in lesions that were injected and in lesions that were not,\" said Jason Chan, MD, Associate Professor in the Department of Radiation Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. An exploratory analysis of plasma samples from 8 patients identified IL-1β as the cytokine with the largest increase from baseline.\n\n## Nanobiotix Funding and JNJ-1900 Partnership Records\n\nNanobiotix is a Paris-based late-stage clinical nanomedicine company developing hafnium oxide nanoparticle radioenhancers and a lipid-based Nanoprimer delivery platform, according to akta.pro [company records](https://akta.pro/company-data). The same records list a global licensing, co-development and commercialization agreement with Johnson & Johnson's Janssen Pharmaceutica NV announced in July 2023, and a collaboration with MD Anderson Cancer Center spanning multiple clinical trials including MDA-0541, MDA-0123, MDA-0618, MDA-1001 and MDA-0122.\n\nFunding records show a May 2026 global offering of about $100 million (€86.1 million) that closed with 2,218,467 ordinary shares and 345,099 pre-funded warrants, alongside a 2025 royalty monetization agreement with HealthCare Royalty Partners for up to $71 million. Total funding on record stands at $524.5 million.\n\n## Earlier Nanobiotix Clinical and Leadership Milestones\n\nIn September 2026, Nanobiotix announced Phase 1 data for JNJ-1900 (NBTXR3) in inoperable recurrent NSCLC showing 79% one-year locoregional control and 70% overall survival, Stock Titan reported. MarketScreener reported the same month that JNJ-1900 (NBTXR3) had achieved European market authorization for soft tissue sarcoma treatment. On October 1, 2026, Nanobiotix appointed Arnd Christ as chief financial officer and executive board member, succeeding Bart Van Rhijn, Stock Titan reported.\n\n## What the Investigators Proposed Next\n\nInvestigators concluded that the preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naive or refractory to anti-PD-1. Nanobiotix Chief Medical Officer Louis Kayitalire said the updated analysis builds on the first data reported with consistent safety and an improvement in overall survival.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}